Clinical trial
Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny
NCT02634060 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- March 31, 2016
- Completion date
- September 5, 2022
- Enrollment
- 140 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.